Overview of Q3 2025 Financial Performance
Swedish Orphan Biovitrum AB (publ) (Sobi) has released its financial results for the third quarter of 2025, showcasing notable growth and performance across its strategic portfolio. Total revenues reached SEK 7,776 million, marking a significant increase of 13 percent, or 21 percent at constant exchange rates (CER). This upward trend reflects Sobi's solid positioning in the market and its dedication to enhancing its product offerings.
Haematology Revenue Surge
The haematology segment reported a remarkable revenue increase of 26 percent at CER, achieving SEK 4,771 million. This growth was primarily propelled by outstanding sales of Altuvoct, which brought in SEK 769 million and strong performance from Doptelet, contributing SEK 1,408 million. Moreover, the sales figures for Aspaveli/Empaveli reached SEK 317 million, although this segment faced some offset from declining Vonjo sales, which fell to SEK 307 million.
Immunology Sector Highlights
In the immunology sector, Sobi also displayed robust performance with a revenue uptick of 12 percent, amounting to SEK 2,658 million. Key sales contributors included Gamifant at SEK 733 million and Kineret at SEK 769 million. However, lower royalties from Beyfortus, totaling SEK 1,166 million, slightly dampened the overall figures.
Strategic Portfolio Growth
The strategic portfolio, encompassing several key products such as Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo, and Zynlonta, registered an impressive growth of 39 percent at CER, achieving SEK 5,001 million. This growth reflects Sobi's commitment to advancing its therapies and expanding its reach in the biopharmaceutical space.
Financial Adjustments and Outlook
Despite these significant revenue gains, Sobi reported an impairment of SEK 6,612 million concerning Vonjo. Despite the impairment, cash flow remained unaffected, and the company noted these figures as items affecting comparability (IAC). The adjusted EBITA margin stood at 47 percent (previously 43 percent). The EBITA figure reached SEK 3,620 million, indicating a healthy margin performance.
Future Projections
Looking ahead, Sobi anticipates revenue growth at a low double-digit percentage at CER, an adjustment from the previously expected high-single-digit percentage. The adjusted EBITA margin is projected to stabilize in the mid-to-high 30s percentage range, reflecting a strategic focus on profitability.
Invitation for Analysts and Investors
To further discuss these results, Sobi will host a conference call on the same day, providing an opportunity for analysts and investors to engage with the management team during a presentation and Q&A session. Details for the call will be communicated to interested participants.
Conclusion
In conclusion, Sobi's financial report for Q3 2025 positions the company favorably within the biopharma industry. With substantial revenue growth in key segments and a resilient strategic portfolio, Sobi continues to solidify its market presence. Stakeholders can look forward to ongoing developments as the company advances its innovative therapies.
Frequently Asked Questions
What were the total revenues for Sobi in Q3 2025?
The total revenues for Sobi in Q3 2025 were SEK 7,776 million, reflecting a 13 percent increase.
How did the haematology segment perform?
The haematology segment saw a remarkable increase in revenue by 26 percent to SEK 4,771 million.
What is the outlook for Sobi's revenue growth?
Sobi anticipates revenue growth at low double-digit percentages at constant exchange rates for the coming periods.
How did the impairment of Vonjo affect Sobi's finances?
Although Sobi reported an impairment of SEK 6,612 million related to Vonjo, the cash flow remained unaffected.
What is the adjusted EBITA margin for Q3 2025?
The adjusted EBITA margin for Sobi in Q3 2025 was 47 percent, up from 43 percent previously.
